JP2021512143A5 - - Google Patents

Info

Publication number
JP2021512143A5
JP2021512143A5 JP2020560615A JP2020560615A JP2021512143A5 JP 2021512143 A5 JP2021512143 A5 JP 2021512143A5 JP 2020560615 A JP2020560615 A JP 2020560615A JP 2020560615 A JP2020560615 A JP 2020560615A JP 2021512143 A5 JP2021512143 A5 JP 2021512143A5
Authority
JP
Japan
Prior art keywords
compound
amino
carboxamide
acetyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020560615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512143A (ja
Filing date
Publication date
Priority claimed from GBGB1801355.7A external-priority patent/GB201801355D0/en
Application filed filed Critical
Publication of JP2021512143A publication Critical patent/JP2021512143A/ja
Publication of JP2021512143A5 publication Critical patent/JP2021512143A5/ja
Priority to JP2023191935A priority Critical patent/JP2024023271A/ja
Pending legal-status Critical Current

Links

JP2020560615A 2018-01-26 2019-01-25 化合物 Pending JP2021512143A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191935A JP2024023271A (ja) 2018-01-26 2023-11-10 化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1801355.7A GB201801355D0 (en) 2018-01-26 2018-01-26 Compounds
GB1801355.7 2018-01-26
PCT/GB2019/050209 WO2019145726A1 (en) 2018-01-26 2019-01-25 Compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191935A Division JP2024023271A (ja) 2018-01-26 2023-11-10 化合物

Publications (2)

Publication Number Publication Date
JP2021512143A JP2021512143A (ja) 2021-05-13
JP2021512143A5 true JP2021512143A5 (cg-RX-API-DMAC7.html) 2022-02-02

Family

ID=61558141

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560615A Pending JP2021512143A (ja) 2018-01-26 2019-01-25 化合物
JP2023191935A Pending JP2024023271A (ja) 2018-01-26 2023-11-10 化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191935A Pending JP2024023271A (ja) 2018-01-26 2023-11-10 化合物

Country Status (32)

Country Link
US (3) US11364246B2 (cg-RX-API-DMAC7.html)
EP (3) EP4699655A3 (cg-RX-API-DMAC7.html)
JP (2) JP2021512143A (cg-RX-API-DMAC7.html)
KR (1) KR102827138B1 (cg-RX-API-DMAC7.html)
CN (2) CN111683926B (cg-RX-API-DMAC7.html)
AU (2) AU2019213211B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020015169A2 (cg-RX-API-DMAC7.html)
CA (1) CA3086747A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001945A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020010552A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200373A (cg-RX-API-DMAC7.html)
DK (1) DK3743406T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091576A1 (cg-RX-API-DMAC7.html)
ES (1) ES2943636T3 (cg-RX-API-DMAC7.html)
FI (1) FI3743406T3 (cg-RX-API-DMAC7.html)
GB (4) GB201801355D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20230294T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061394T2 (cg-RX-API-DMAC7.html)
IL (1) IL276034B2 (cg-RX-API-DMAC7.html)
LT (1) LT3743406T (cg-RX-API-DMAC7.html)
MA (1) MA51669B1 (cg-RX-API-DMAC7.html)
MX (1) MX2020007899A (cg-RX-API-DMAC7.html)
PE (1) PE20210657A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551327A1 (cg-RX-API-DMAC7.html)
PL (1) PL3743406T3 (cg-RX-API-DMAC7.html)
PT (1) PT3743406T (cg-RX-API-DMAC7.html)
RS (1) RS64073B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006067XA (cg-RX-API-DMAC7.html)
SI (1) SI3743406T1 (cg-RX-API-DMAC7.html)
TW (1) TWI908705B (cg-RX-API-DMAC7.html)
WO (1) WO2019145726A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202003856B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
KR20220050126A (ko) * 2019-06-12 2022-04-22 티엠이엠16에이 리미티드 호흡기 질환을 치료하기 위한 화합물
EP4003516A1 (en) * 2019-07-24 2022-06-01 Tmem16A Limited Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
GB201910666D0 (en) * 2019-07-25 2019-09-11 Enterprise Therapeutics Ltd Novel form of compounds
GB201910665D0 (en) * 2019-07-25 2019-09-11 Enterprise Therapeutics Ltd Novel form of compounds
GB201910664D0 (en) * 2019-07-25 2019-09-11 Enterprise Therapeutics Ltd Novel forms of compound
KR20220052934A (ko) * 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
US12612367B2 (en) * 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
AU2021263914B2 (en) 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
EP4192811A1 (en) 2020-08-10 2023-06-14 Dana-Farber Cancer Institute, Inc. Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
TW202237090A (zh) 2020-12-11 2022-10-01 英商Tmem16A有限公司 治療呼吸道疾病之化合物
EP4274828A1 (en) 2021-01-06 2023-11-15 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2022150173A1 (en) 2021-01-06 2022-07-14 AbbVie Global Enterprises Ltd. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
CN120476113A (zh) * 2022-12-20 2025-08-12 杭州中美华东制药有限公司 具有sting抑制作用的含肟化合物及其药物组合物和用途
KR20260113070A (ko) * 2023-11-15 2026-07-21 릴레이 테라퓨틱스, 인크. PI3Kα 저해제 그리고 이의 제조 방법 및 사용 방법

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT69524A (en) 1990-11-19 1995-09-28 Christ Ag Process and apparatus for desalinization of water soluble liquids
US6388054B1 (en) * 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
GB0129267D0 (en) 2001-12-06 2002-01-23 Syngenta Ltd Fungicides
AU2003248122A1 (en) * 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
AU2003301443A1 (en) * 2002-10-18 2004-05-04 E.I. Du Pont De Nemours And Company Azolecarboxamide herbicides
WO2004106324A1 (en) * 2003-05-27 2004-12-09 E.I. Dupont De Nemours And Company Azolecarboxamide herbicides
CN100545161C (zh) * 2003-08-15 2009-09-30 中国科学院上海药物研究所 一类杂环衍生物、制备方法及其用途
US20060069132A1 (en) * 2004-04-07 2006-03-30 Armel Gregory R Azolecarboxamide herbicides
CN101180854B (zh) * 2005-04-25 2015-02-18 Lg电子株式会社 读取器控制系统
US7754717B2 (en) * 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP2069313A2 (en) * 2006-06-29 2009-06-17 Alantos Pharmaceuticals Holdings, Inc. Metalloprotease inhibitors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2072501A1 (en) * 2007-12-21 2009-06-24 Bayer CropScience AG Aminobenzamide derivatives as useful agents for controlling animal parasites
AU2009243756B2 (en) * 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
PE20110063A1 (es) * 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
EP2184273A1 (de) * 2008-11-05 2010-05-12 Bayer CropScience AG Halogen-substituierte Verbindungen als Pestizide
EP2751107A1 (en) 2011-09-01 2014-07-09 Irm Llc Compounds and compositions as pdgfr kinase inhibitors
US8883819B2 (en) * 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US9688637B2 (en) * 2014-08-21 2017-06-27 Northwestern Universtiy 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members
WO2016097918A1 (en) 2014-12-18 2016-06-23 Pfizer Inc. Pyrimidine and triazine derivatives and their use as axl inhibitors
WO2017083971A1 (en) * 2015-11-16 2017-05-26 University Of Manitoba Compositions and methods for treatment of influenza
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
US20200361871A1 (en) 2018-01-26 2020-11-19 Enterprise Therapeutics Ltd. Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201910665D0 (en) 2019-07-25 2019-09-11 Enterprise Therapeutics Ltd Novel form of compounds

Similar Documents

Publication Publication Date Title
GB2583882A (en) Compounds
US10195213B2 (en) Chemical entities that kill senescent cells for use in treating age-related disease
EP1833799B1 (en) 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
CN1428145A (zh) 用作速激肽nk3受体拮抗剂的喹啉衍生物
RU2008136553A (ru) Производные бензотиазола в качестве агонистов бета2 адренорецептора
JP2013510883A5 (cg-RX-API-DMAC7.html)
CA2895448A1 (en) Autotaxin inhibitors
JP2013523636A5 (cg-RX-API-DMAC7.html)
JP2023544716A5 (cg-RX-API-DMAC7.html)
JP2020537658A5 (cg-RX-API-DMAC7.html)
RU2015114937A (ru) Замещенные соединения карбамата и их применение в качестве антагонистов канала с транзиторным рецепторным потенциалом (trp)
JP2022535986A5 (cg-RX-API-DMAC7.html)
JP2022541311A5 (cg-RX-API-DMAC7.html)
MXPA05003105A (es) Compuestos de amonio cuaternario.
JP2023507188A5 (cg-RX-API-DMAC7.html)
JP2022541638A5 (cg-RX-API-DMAC7.html)
CN120435316A (zh) 包括金属通道激活剂和nmda受体拮抗剂的组合疗法
JP2025500346A (ja) 睡眠時無呼吸の治療のためのα2-アドレナリン受容体サブタイプC(アルファ-2C)アンタゴニストとムスカリン受容体アンタゴニストとの組合せ
WO2024054807A1 (en) Combination therapies including metal channel activators and tdp-43 modulators
KR20240124995A (ko) 수면 무호흡의 치료를 위한 a2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 노르에피네프린 재흡수 억제제의 조합물
JP2023503470A5 (cg-RX-API-DMAC7.html)
EA046966B1 (ru) Соединения
UA91350C2 (uk) Похідні 3-фенілпіразолу як модулятори 5-ht2a серотонінового рецептора, корисні для лікування розладів, пов'язаних з цим рецептором
HK1118552A (en) 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto